This is a working overview of CAS Registry Number, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
=== Healthcare === The Ajinomoto Group's healthcare business is based on using the fermentation technology of amino acids. In 1956, Ajinomoto began producing the world's first amino acid infusion, enteral nutrition products, and crystalline amino acids that could be used as raw materials in pharmaceutical products. Currently, Ajinomoto manufactures around twenty kinds of amino acids at various factories overseas, including plants in Japan, the United States, Europe, and India. In 1995, Ajinomoto began selling an amino acid supplement called Amino Vital for professional sports athletes. In 2011, Ajinomoto began offering an "Amino Index" health checkup, which statistically analyzes the difference in amino acid concentrations between healthy individuals and adults suffering from cancer and other serious diseases to aid the early detection of cancer and other diseases. In addition to glutamates as a seasoning, the company also produces other amino acids such as L-Leucine, L-Tyrosine, Glycine, and L-Phenylalanine, which it markets as dietary supplements under the brand name AjiPure.
Crystallization analysis fractionation (CRYSTAF): instrument intended for the fast measurement of the chemical composition distribution (CCD) in polyolefins (crystallization analysis fractionation). Temperature rising elution fractionation (TREF): for the characterization of CCD in polyolefins. Crystallization elution fractionation (CEF): high-throughput chemical composition distribution analyzer by CEF TGIC: technique for the analysis of low crystallinity polyolefins implemented by a fully automated instrument. Molar mass distribution GPC-IR: high temperature gel permeation chromatography (GPC) for polyolefin molar mass distribution. It works with concentration and composition detectors (infrared), viscometer and light scattering. GPC One: GPC calculations software. Data Unit 200: signals device for gel permeation chromatography instruments. GPC-QC: simplified and fully automated GPC instrument aimed at control laboratories in polyolefin production plants. Intrinsic viscosity IVA: automated instrument for intrinsic viscosity analysis of polymers with dissolution temperature up to 200 °C. Bivariate distribution Cross-fractionation chromatography(CFC) instrument to analyze the polyolefin bivariate distribution by TREF and gel permeation chromatography. SGIC 2D: 3D results with the advantages of using an IR detector for this new tool aimed at polyolefin characterization. Preparative fractionation PREP mc2: preparative instrument to fractionate polymers by molar mass or composition (TREF or CRYSTAF).
=== Morphological variation === Plants exhibit natural variation in their form and structure. While all organisms vary from individual to individual, plants exhibit an additional type of variation. Within a single individual, parts are repeated which may differ in form and structure from other similar parts. This variation is most easily seen in the leaves of a plant, though other organs such as stems and flowers may show similar variation. There are three primary causes of this variation: positional effects, environmental effects, and juvenility.
Diabetes is a chronic disease, i.e. it cannot be cured, but symptoms and complications can be minimized with proper treatment. Diabetes can lead to elevated blood sugar levels, which in turn can lead to damage to the heart, blood vessels, kidneys, eyes and nerves. There are very few studies on how to treat LADA, specifically, which is probably due to difficulties in classifying and diagnosing the disease. LADA patients often do not need insulin treatment immediately after being diagnosed because their own insulin production decreases more slowly than T1D patients, but in the long run they will need it. About 80% of all LADA patients initially misdiagnosed with type 2 (and who have GAD antibodies) will become insulin-dependent within 3 to 15 years (according to differing LADA sources). The treatment for Type 1 diabetes/LADA is exogenous insulin to control glucose levels, prevent further destruction of residual beta cells, reduce the possibility of diabetic complications, and prevent death from diabetic ketoacidosis (DKA). Although LADA may appear to initially respond to similar treatment (lifestyle and medications) as type 2 diabetes, this will not halt or slow the progression of beta cell destruction; people with LADA will eventually become insulin-dependent. People with LADA have insulin resistance comparable to long-term type 1 diabetes; some studies found that people with LADA have less insulin resistance than those with type 2 diabetes, but others found no difference.
Sources: en.wikipedia.org
For centuries, hair removal has long shaped gender roles, served to signify social status and defined notions of femininity and the ideal "body image". In early periods, the condition of being hairless was mostly done as a way to keep the body clean, using flint, seashells, beeswax and various other depilatory utensils and exfoliator substances, some highly questionable and highly caustic. Ancient Rome also associated hair removal with status: a person with smooth skin was associated with purity and superiority. Removing body hair was done by both men and women. Psilothrum or psilotrum (Ancient Greek: ψίλωθρον) and dropax (Ancient Greek: δρῶπαξ) were depilatories in ancient Greece and Rome. An alipilus (Ancient Greek: παρατίλτριος) was a slave who attended bathers, removing unwanted body hair. The same practice applied to women, who were served by female slaves called παρατίλτριαι (the plural of παρατίλτρια, the feminine form of παρατίλτριος). In Ancient Egypt, besides being a fashion statement for affluent Egyptians of all genders, hair removal served as a treatment for louse infestation, which was a prevalent issue in the region. Very often, they would replace the removed head hair with a Nubian wig, which was seen as easier to maintain and also fashionable. Ancient Egyptian priests also shaved or depilated all over daily, so as to present a "pure" body before the images of the gods.
As the rate of gas seepage slowly decreases, the shorter-lived, methane-hungry mussels (or more precisely, their methane-hungry bacterial symbionts) start to die off. At this stage, tubeworms become the dominant organism in a seep community. As long as there is some sulfide in the sediment, the sulfide-mining tubeworms can persist. Individuals of one tubeworm species Lamellibrachia luymesi have been estimated to live for over 250 years in such conditions.
Atha sold coffee in the California area, but proposed to James Folger II that he open and manage a Folgers Coffee plant in Texas. The company grew exponentially after Atha opened the Texas plant. Under the mid-20th century leadership of Peter Folger, the brand became one of the principal coffee concerns in North America. In 1960, the construction of a Folger Coffee Company plant in New Orleans was started due to new shipping routes from Central America. Procter & Gamble acquired Folger's in 1963 and removed the apostrophe from its name. On August 9, 1969, company heiress Abigail Folger was stabbed to death in Los Angeles as part of the Manson Family's Tate–LaBianca murders. P&G announced in January 2008 that Folgers would be spun off into a separate Cincinnati-based company but reversed itself that June and announced Folgers would be acquired by the end of 2008 by The J.M. Smucker Company. Utilizing a rare financial technique called a Reverse Morris Trust, Smucker purchased Folgers in November 2008 and made it a subsidiary.
Sources: en.wikipedia.org
=== Use in traditional medicine === In modern South Korea, S. mutilans and other Scolopendra species are used in Korean traditional medicine. The centipedes are used whole to treat various medical issues, including joint problems (which is its major use), alopecia areata, stroke, convulsions, lymphangitis, lumps or masses, neoplasm, poisonous tumours, carbuncles, and snake bites. These centipedes were considered one of the most prescribed, medically important, and expensive insect/arthropod drugs in Korean traditional medicine. They are frequently prescribed alone, despite arthropod drugs are usually prescribed with a mix of other medicinal materials for desired effects. In China, S. mutilans is the only centipede species registered for clinical application by the Pharmacopeia of the People's Republic of China. Despite being the only species listed, other species of centipedes, including S. mojiangica, S. multidens, and S. negrocapitis, were also regularly used as substitutes in clinical practice.
== Cause == Schwartz–Jampel syndrome is caused by mutations in the HSPG2 gene, which makes the protein perlecan, which is found in muscle and cartilage. Relationships between the disease and perlecan deficiency have been studied. In Schwartz–Jampel syndrome, it is suspected that abnormal perlecan function leads to a deficiency in acetylcholinesterase, an enzyme involved in breaking down the neurotransmitter acetylcholine, which incites muscle contraction. If acetylcholine is not broken down, it can lead to prolonged muscle contraction/stiffening of the muscles (myotonia). The condition is believed to follow an autosomal recessive inheritance pattern, although some reported cases suggest an autosomal dominant inheritance pattern.
By July, the Centre was the only non-Nazi party that still even nominally existed; the SPD and KPD had been banned outright, while the others had been browbeaten into dissolving themselves. On 1 July, Papen and Kaas agreed that as part of the concordat, German priests would stay out of politics. As it turned out, the party dissolved on 5 July—much to the dismay of Cardinal Pacelli, who felt the party should at least have waited until after the conclusion of negotiations. The day after, the government issued a law outlawing the formation of new political parties, thereby making the NSDAP the only legally permitted party in Germany.
When the type of snake is unknown, antivenom is often given based on the types known to be in the area. In some areas of the world, getting the right type of antivenom is difficult and this partly contributes to why they sometimes do not work. An additional issue is the cost of these medications. Antivenom has little effect on the area around the bite itself. Supporting the person's breathing is sometimes also required. The number of venomous snakebites that occur each year may be as high as five million. They result in about 2.5 million envenomations and 20,000 to 125,000 deaths. The frequency and severity of bites vary greatly among different parts of the world. They occur most commonly in Africa, Asia, and Latin America, with rural areas more greatly affected. Deaths are relatively rare in Australia, Europe and North America. For example, in the United States, about seven to eight thousand people per year are bitten by venomous snakes (about one in 40 thousand people) and about five people die (about one death per 65 million people).
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.